Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of a solid tumor malignancy that is not responsive to standard therapy(ies) or for which there is no approved therapy
Patients must have acceptable laboratory requirements
Left ventricular ejection fraction as measured by echocardiogram or multiple-gated acquisition scan that is above the institutional lower level of normal or greater than 50%
Has experienced resolution of toxic effect(s) of the most recent prior chemotherapy and/or prior surgical and radiation treatment
Must be able to understand and give written informed consent and comply with study procedures

Exclusion Criteria:

If the patient has brain metastasis, they must have stable neurologic status without the use of steroids or on a stable or decreasing dose of steroids
Presence of clinically significant gastrointestinal abnormalities that may affect the absorption of study treatments
A medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk in the opinion of the Investigator
Patient has a concomitant cardiovascular issue that precludes adequate study treatment compliance or increases patient risk
Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study
Prior anti-cancer monoclonal antibody within 4 weeks prior to baseline
Currently enrolled in another investigational study
Has disease that is suitable for approved therapy administered with curative intent